Action on 'comparators' will take time and 'trade-offs'

This is a preview of subscriber content

Subscribe now to continue reading.

Achieving any change on 'comparators' through the Access to Medicines Working Group would represent an historic change akin the creation of patent-based formularies - it will be just as hard. It will take time, and a willingness to 'trade', but Medicines Australia is close to securing a framework that could help deliver that change. …

Subscribe now to continue reading.

Action on 'comparators' will take time and 'trade-offs'

This is a preview of subscriber content

Latest Video

Most Read

Lilly's Mounjaro will not be listed on PBS because of 'unrealistic' recommendation

Quarter of a century after the case that led to the PBAC's unaccountability loop

Outcomes deliver disappointment for vaccine advocates but progress on paediatric access to biologics

This makes it twice in two weeks, so at what point do we accept there's a problem?

'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'

New Stories

Moderna taps Salesforce to unify global commercial operations

How do we know the HTA institution loves patients? Because they use a love heart emoji

Australian company secures capital raise to advance amsulostat trials and strengthen pipeline

Australia urged to strengthen sunscreen literacy and label clarity

'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'

We need to say it again, just in case, that this advice is about ministerial choices and not conditions

Families welcome cancer drug progress but remain cautious over timely access

Sign In

Action on 'comparators' will take time and 'trade-offs'

This is a preview of subscriber content

Latest Video

Most Read

Lilly's Mounjaro will not be listed on PBS because of 'unrealistic' recommendation

Quarter of a century after the case that led to the PBAC's unaccountability loop

Outcomes deliver disappointment for vaccine advocates but progress on paediatric access to biologics

This makes it twice in two weeks, so at what point do we accept there's a problem?

'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'

Follow Us

New Stories

Moderna taps Salesforce to unify global commercial operations

How do we know the HTA institution loves patients? Because they use a love heart emoji

Australian company secures capital raise to advance amsulostat trials and strengthen pipeline

Australia urged to strengthen sunscreen literacy and label clarity

'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'

We need to say it again, just in case, that this advice is about ministerial choices and not conditions

Families welcome cancer drug progress but remain cautious over timely access